28 Results for "

Iron overload

" in MedChemExpress (MCE) Product Catalog:
Products (28)

28 Results for "Iron overload" in MCE Product Catalog:

36
36 Publications Verification
Cat. No.: HY-B1645
CAS No.: 1185-57-5
Synonyms: Ammonium ferric citrate; FAC
Ammonium iron(III) citrate (Ammonium ferric citrate), a physiological form of nonetransferrin-bound iron, induces intracellular iron overload to cause ferroptosis . Ammonium iron(III) citrate can enhance protein production .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-17359
CAS No.: 201530-41-8
Synonyms: ICL 670
Target:  

Bacterial Ferroptosis

Research Areas:  

Cancer

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114758
CAS No.: 737-86-0
Purity:  99.96%
Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-126301
CAS No.: 1354790-56-9
Purity:  99.79%
Target:  

Ferroportin

Research Areas:  

Metabolic Disease

DMT1 blocker 1 is an orally active blocker of divalent metal transporter 1 (DMT1) with an IC50 of 0.64 μM. DMT1 blocker 1 inhibits intestinal cell absorption of non-heme iron, thereby alleviating iron overload by blocking the DMT1 transporter. DMT1 blocker 1 demonstrates significant efficacy in rodent models of acute iron hyperabsorption. DMT1 blocker 1 is useful for studying iron overload disorders such as hereditary hemochromatosis and thalassemia .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-111914A
CAS No.: 14875-96-8
Purity:  99.70%
Ferroheme is the ferrous form of heme in hemoglobin, reversibly binding oxygen as an oxygen carrier. Its free form induces oxidative stress and ferroptosis by releasing iron ions, which catalyze reactive oxygen species generation via Fenton reactions, leading to lipid peroxidation and cell death. This mechanism is critical in pathological contexts like intracerebral hemorrhage and neurodegenerative diseases, making it a target for studying iron-overload disorders and ferroptosis-related pathologies[1][2][3].
loading...
    loading...
Cat. No.: HY-108260
CAS No.: 239101-33-8
Purity:  99.32%
Synonyms: GT-56-252
Target:  

Ferroptosis

Research Areas:  

Cardiovascular Disease

Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .
loading...
    loading...
Cat. No.: HY-N0444
CAS No.: 117-02-2
Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections .
loading...
    loading...
Cat. No.: HY-122620
CAS No.: 2114365-78-3
Purity:  98.33%
Synonyms: Hetrombopag (tautomerism); SHR-8735 (tautomerism)
Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
loading...
    loading...
Cat. No.: HY-114837
CAS No.: 35998-29-9
Purity:  98.00%
Target:  

Ferroptosis

Research Areas:  

Cancer

HBED is a potent iron chelator. HBED can be used to study transfusional iron overload .
loading...
    loading...
Cat. No.: HY-P3494
CAS No.: 1356390-47-0
Target:  

Hepcidin Bacterial

Research Areas:  

Infection Inflammation/Immunology

Hepcidin-25 (human) is an iron metabolism regulator and Antimicrobial agent. Hepcidin-25 (human) exerts anti-inflammatory and antimicrobial activities by regulating iron-mediated oxidative damage .
loading...
    loading...
Cat. No.: HY-P99720A
CAS No.: 1373715-00-4
Synonyms: RAP-536

Target:  

TGF-beta/Smad

Research Areas:  

Metabolic Disease

Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .
loading...
    loading...
Cat. No.: HY-145589
CAS No.: 2600513-51-5
Synonyms: Hetrombopag; SHR-8735
Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
loading...
    loading...
Cat. No.: HY-175806
CAS No.: 1372792-51-2
Research Areas:  

Cancer

CS47 is a Thioredoxin Reductase 1 (TRXR1) inhibitor and ferroptosis inducer. CS47 binds non-covalently to sites between the FAD and NADPH pockets of TRXR1. CS47 drives glutathione depletion, lipid reactive oxygen species accumulation, HMOX1-dependent iron overload, and selective cytotoxicity in lung cancer cells. CS47 can be used for the research of lung cancer .
loading...
    loading...
Cat. No.: HY-147278
CAS No.: 2646704-10-9
Synonyms: Divesiran; SLN124
Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .
loading...
    loading...
Cat. No.: HY-P11260
CAS No.: 3051556-89-6
Research Areas:  

Metabolic Disease

MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC50 for recombinant human TMPRSS6 protein of 22 nM and a Ki of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC50 of 352 nM and a Ki of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with Ki of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) .
loading...
    loading...
Cat. No.: HY-17359S
CAS No.: 1133425-75-8
Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
loading...
    loading...
Cat. No.: HY-17359R
CAS No.: 201530-41-8
Synonyms: ICL 670 (Standard)
Research Areas:  

Cancer

Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
loading...
    loading...
Cat. No.: HY-147278A
Synonyms: Divesiran sodium; SLN124 sodium
Manusiran sodium (Divesiran sodium) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran sodium increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran sodium with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran sodium can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .
loading...
    loading...
Cat. No.: HY-N0444R
CAS No.: 117-02-2
Rubiadin (Standard) is the analytical standard of Rubiadin (HY-N0444). This product is intended for research and analytical applications. Rubiadin is an orally active free radical scavenger that inhibits the activation of the NF-κB pathway. Rubiadin inhibits osteoclast formation, bone resorption, lipid peroxidation, HBV DNA replication and cancer cell proliferation; reduces pro-inflammatory cytokine levels; induces cancer cell apoptosis; and possesses antifungal, antimalarial, antibacterial and anticonvulsant activities. Rubiadin can be used in the research of osteoporosis, acute inflammation, chronic inflammation, carbon tetrachloride-induced liver injury, Alzheimer's disease, breast cancer, iron overload disorders, hepatitis B virus infection, colon cancer, liver cancer, T-lymphocytic leukemia, cervical cancer, diabetic nephropathy, epileptic seizures, fungal infections, malaria and bacterial infections.
loading...
    loading...
Cat. No.: HY-17359S1
CAS No.: 1261392-79-3
Synonyms: ICL 670-13C6
Deferasirox- 13C6 (ICL 670- 13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload .
loading...
    loading...